Skip to main content
Erschienen in: Die Pathologie 2/2019

17.07.2018 | Lymphome | Übersichten

Revidierte Fassung der 4. Ausgabe der WHO-Klassifikation maligner Lymphome

Was ist neu?

verfasst von: Prof. Dr. G. Ott, W. Klapper, A. C. Feller, M. L. Hansmann, P. Möller, H. Stein, A. Rosenwald, F. Fend

Erschienen in: Die Pathologie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Nach 8 Jahren liegt nun eine Neufassung der 4. Ausgabe der WHO-Klassifikation lymphatischer Neoplasien vor. Sie beinhaltet sowohl eine konzeptionelle Neufassung bestehender Entitäten wie auch – wenige – provisorische neue Entitäten bzw. Kategorien, vor allem unter den aggressiven B‑Zell-Lymphomen. Hier sind vor allem das High-grade-B-Zell-Lymphom, das großzellige B‑Zell-Lymphom mit IRF4-Translokation und das Burkitt-ähnliche Lymphom mit Aberrationen in 11q zu nennen. Von besonderer Bedeutung sind auch neuere Konzepte zur Taxonomie und Klassifikation früher lymphatischer Läsionen bzw. möglicher Vorstufen, wie die in-situ follikuläre Neoplasie und die in-situ Mantelzellneoplasie, die Beschreibung indolenter Lymphoproliferationen wie das Brustimplantat-assoziierte anaplastische großzellige Lymphom und die indolente T‑Zell-Lymphoproliferation des Gastrointestinaltrakts sowie generell die Schärfung diagnostischer Kriterien bestehender Entitäten.
Literatur
1.
Zurück zum Zitat Adam P, Katzenberger T, Eifert M et al (2005) Presence of preserved reactive germinal centers in follicular lymphoma is a strong histopathologic indicator of limited disease stage. Am J Surg Pathol 29(12):1661–1664PubMed Adam P, Katzenberger T, Eifert M et al (2005) Presence of preserved reactive germinal centers in follicular lymphoma is a strong histopathologic indicator of limited disease stage. Am J Surg Pathol 29(12):1661–1664PubMed
2.
Zurück zum Zitat Bacon CM, Ye H, Diss TC et al (2007) Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol 31(7):1050–1058PubMed Bacon CM, Ye H, Diss TC et al (2007) Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol 31(7):1050–1058PubMed
3.
Zurück zum Zitat Bodor C, Grossmann V, Popov N et al (2013) EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122(18):3165–3168PubMedPubMedCentral Bodor C, Grossmann V, Popov N et al (2013) EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122(18):3165–3168PubMedPubMedCentral
4.
Zurück zum Zitat Bruscaggin A, Monti S, Arcaini L et al (2014) Molecular lesions of signalling pathway genes in clonal B‑cell lymphocytosis with marginal zone features. Br J Haematol 167(5):718–720PubMed Bruscaggin A, Monti S, Arcaini L et al (2014) Molecular lesions of signalling pathway genes in clonal B‑cell lymphocytosis with marginal zone features. Br J Haematol 167(5):718–720PubMed
5.
Zurück zum Zitat Cairns RA, Iqbal J, Lemonnier F et al (2012) IDH2 mutations are frequent in angioimmunoblastic T‑cell lymphoma. Blood 119(8):1901–1903PubMedPubMedCentral Cairns RA, Iqbal J, Lemonnier F et al (2012) IDH2 mutations are frequent in angioimmunoblastic T‑cell lymphoma. Blood 119(8):1901–1903PubMedPubMedCentral
6.
7.
Zurück zum Zitat Clemens MW, Medeiros LJ, Butler CE et al (2016) Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol 34(2):160–168PubMed Clemens MW, Medeiros LJ, Butler CE et al (2016) Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol 34(2):160–168PubMed
8.
Zurück zum Zitat Fan Z, Natkunam Y, Bair E et al (2003) Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 27(10):1346–1356PubMed Fan Z, Natkunam Y, Bair E et al (2003) Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 27(10):1346–1356PubMed
9.
Zurück zum Zitat Feldman AL, Dogan A, Smith DI et al (2011) Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 117(3):915–919PubMedPubMedCentral Feldman AL, Dogan A, Smith DI et al (2011) Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 117(3):915–919PubMedPubMedCentral
10.
Zurück zum Zitat Gibson SE, Swerdlow SH, Ferry JA et al (2011) Reassessment of small lymphocytic lymphoma in the era of monoclonal B‑cell lymphocytosis. Haematologica 96(8):1144–1152PubMedPubMedCentral Gibson SE, Swerdlow SH, Ferry JA et al (2011) Reassessment of small lymphocytic lymphoma in the era of monoclonal B‑cell lymphocytosis. Haematologica 96(8):1144–1152PubMedPubMedCentral
11.
Zurück zum Zitat Gine E, Martinez A, Villamor N et al (2010) Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95(9):1526–1533PubMedPubMedCentral Gine E, Martinez A, Villamor N et al (2010) Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95(9):1526–1533PubMedPubMedCentral
12.
Zurück zum Zitat Green TM, Nielsen O, de Stricker K et al (2012) High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B‑cell lymphoma. Am J Surg Pathol 36(4):612–619PubMed Green TM, Nielsen O, de Stricker K et al (2012) High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B‑cell lymphoma. Am J Surg Pathol 36(4):612–619PubMed
13.
Zurück zum Zitat Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B‑cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282PubMed Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B‑cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282PubMed
14.
Zurück zum Zitat Hartmann S, Doring C, Jakobus C et al (2013) Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma – endpoints of a spectrum of one disease? PLoS ONE 8(11):e78812PubMedPubMedCentral Hartmann S, Doring C, Jakobus C et al (2013) Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma – endpoints of a spectrum of one disease? PLoS ONE 8(11):e78812PubMedPubMedCentral
15.
Zurück zum Zitat Hartmann S, Eichenauer DA, Plutschow A et al (2013) The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma. Blood 122(26):4246–4252PubMed Hartmann S, Eichenauer DA, Plutschow A et al (2013) The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma. Blood 122(26):4246–4252PubMed
16.
Zurück zum Zitat Hartmann S, Doring C, Vucic E et al (2015) Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br J Haematol 169(3):415–422PubMed Hartmann S, Doring C, Vucic E et al (2015) Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br J Haematol 169(3):415–422PubMed
17.
Zurück zum Zitat Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B‑cell lymphoma. Blood 121(12):2253–2263PubMed Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B‑cell lymphoma. Blood 121(12):2253–2263PubMed
18.
Zurück zum Zitat Horn H, Ziepert M, Wartenberg M et al (2015) Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B‑cell lymphoma. Leukemia 29(7):1564–1570PubMed Horn H, Ziepert M, Wartenberg M et al (2015) Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B‑cell lymphoma. Leukemia 29(7):1564–1570PubMed
19.
Zurück zum Zitat Iqbal J, Wright G, Wang C et al (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T‑cell lymphoma. Blood 123(19):2915–2923PubMedPubMedCentral Iqbal J, Wright G, Wang C et al (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T‑cell lymphoma. Blood 123(19):2915–2923PubMedPubMedCentral
20.
21.
Zurück zum Zitat Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B‑cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452–3459PubMedPubMedCentral Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B‑cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452–3459PubMedPubMedCentral
22.
Zurück zum Zitat Katzenberger T, Kalla J, Leich E et al (2009) A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 113(5):1053–1061PubMed Katzenberger T, Kalla J, Leich E et al (2009) A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 113(5):1053–1061PubMed
23.
Zurück zum Zitat Landgren O, Albitar M, Ma W et al (2009) B‑cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 360(7):659–667PubMedPubMedCentral Landgren O, Albitar M, Ma W et al (2009) B‑cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 360(7):659–667PubMedPubMedCentral
24.
Zurück zum Zitat Leich E, Salaverria I, Bea S et al (2009) Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 114(4):826–834PubMedPubMedCentral Leich E, Salaverria I, Bea S et al (2009) Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 114(4):826–834PubMedPubMedCentral
25.
Zurück zum Zitat Lemonnier F, Couronné L, Parrens M et al (2012) Recurrent TET2 mutations in peripheral T‑cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 120(7):1466–1469PubMed Lemonnier F, Couronné L, Parrens M et al (2012) Recurrent TET2 mutations in peripheral T‑cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 120(7):1466–1469PubMed
26.
Zurück zum Zitat Louissaint AJ, Ackerman AM, as-Santagata D et al (2012) Pediatric-type nodal follicular lymphoma. Blood 120(12):2395–2404PubMed Louissaint AJ, Ackerman AM, as-Santagata D et al (2012) Pediatric-type nodal follicular lymphoma. Blood 120(12):2395–2404PubMed
27.
Zurück zum Zitat Mamessier E, Broussais-Guillaumot F, Chetaille B et al (2014) Nature and importance of follicular lymphoma precursors. Haematologica 99(5):802–810PubMedPubMedCentral Mamessier E, Broussais-Guillaumot F, Chetaille B et al (2014) Nature and importance of follicular lymphoma precursors. Haematologica 99(5):802–810PubMedPubMedCentral
28.
Zurück zum Zitat Masque-Soler N, Szczepanowski M, Kohler CW et al (2013) Molecular classification of mature aggressive B‑cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. Blood 122(11):1985–1986PubMed Masque-Soler N, Szczepanowski M, Kohler CW et al (2013) Molecular classification of mature aggressive B‑cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. Blood 122(11):1985–1986PubMed
29.
Zurück zum Zitat Miranda RN, Aladily TN, Prince HM et al (2014) Breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol 32(2):114–120PubMed Miranda RN, Aladily TN, Prince HM et al (2014) Breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol 32(2):114–120PubMed
30.
Zurück zum Zitat Morabito F, Mosca L, Cutrona G et al (2013) Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia. Clin Cancer Res 19(21):5890–5900PubMed Morabito F, Mosca L, Cutrona G et al (2013) Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia. Clin Cancer Res 19(21):5890–5900PubMed
31.
Zurück zum Zitat Nicolae A, Pittaluga S, Abdullah S et al (2015) EBV-positive large B‑cell lymphomas in young patients. Blood 126(7):863–872PubMedPubMedCentral Nicolae A, Pittaluga S, Abdullah S et al (2015) EBV-positive large B‑cell lymphomas in young patients. Blood 126(7):863–872PubMedPubMedCentral
32.
Zurück zum Zitat Pasqualucci L, Dalla-Favera R (2015) The genetic landscape of diffuse large B‑cell lymphoma. Semin Hematol 52(2):67–76PubMedPubMedCentral Pasqualucci L, Dalla-Favera R (2015) The genetic landscape of diffuse large B‑cell lymphoma. Semin Hematol 52(2):67–76PubMedPubMedCentral
33.
Zurück zum Zitat Perry AM, Warnke RA, Hu Q et al (2013) Indolent T‑cell lymphoproliferative disease of the gastrointestinal tract. Blood 122(22):3599–3606PubMedPubMedCentral Perry AM, Warnke RA, Hu Q et al (2013) Indolent T‑cell lymphoproliferative disease of the gastrointestinal tract. Blood 122(22):3599–3606PubMedPubMedCentral
34.
Zurück zum Zitat Petrella T, Maubec E, Cornillet-Lefebvre P et al (2007) Indolent CD8-positive lymphoid proliferation of the ear. Am J Surg Pathol 31(12):1887–1892PubMed Petrella T, Maubec E, Cornillet-Lefebvre P et al (2007) Indolent CD8-positive lymphoid proliferation of the ear. Am J Surg Pathol 31(12):1887–1892PubMed
35.
Zurück zum Zitat Pillai RK, Surti U, Swerdlow SH (2013) Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies. Haematologica 98(10):1571–1580PubMedPubMedCentral Pillai RK, Surti U, Swerdlow SH (2013) Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies. Haematologica 98(10):1571–1580PubMedPubMedCentral
36.
Zurück zum Zitat Rawstron AC, Shanafelt T, Lanasa MC et al (2010) Different biology and clinical outcome according to the absolute numbers of clonal B‑cells in monoclonal B‑cell lymphocytosis (MBL). Cytometry B Clin Cytom 78(Suppl 1):S19–S23PubMedPubMedCentral Rawstron AC, Shanafelt T, Lanasa MC et al (2010) Different biology and clinical outcome according to the absolute numbers of clonal B‑cells in monoclonal B‑cell lymphocytosis (MBL). Cytometry B Clin Cytom 78(Suppl 1):S19–S23PubMedPubMedCentral
37.
Zurück zum Zitat Richter J, Schlesner M, Hoffmann S et al (2012) Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44(12):1316–1320PubMed Richter J, Schlesner M, Hoffmann S et al (2012) Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44(12):1316–1320PubMed
38.
Zurück zum Zitat Rossi D, Khiabanian H, Spina V et al (2014) Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123(14):2139–2147PubMedPubMedCentral Rossi D, Khiabanian H, Spina V et al (2014) Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123(14):2139–2147PubMedPubMedCentral
39.
Zurück zum Zitat Royo C, Navarro A, Clot G et al (2012) Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 26(8):1895–1898PubMedPubMedCentral Royo C, Navarro A, Clot G et al (2012) Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 26(8):1895–1898PubMedPubMedCentral
40.
Zurück zum Zitat Sakata-Yanagimoto M, Enami T, Yokoyama Y et al (2014) Disease-specific mutations in mature lymphoid neoplasms. Cancer Sci 105(6):623–629PubMedPubMedCentral Sakata-Yanagimoto M, Enami T, Yokoyama Y et al (2014) Disease-specific mutations in mature lymphoid neoplasms. Cancer Sci 105(6):623–629PubMedPubMedCentral
41.
Zurück zum Zitat Salaverria I, Philipp C, Oschlies I et al (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B‑cell lymphoma affecting predominantly children and young adults. Blood 118(1):139–147PubMed Salaverria I, Philipp C, Oschlies I et al (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B‑cell lymphoma affecting predominantly children and young adults. Blood 118(1):139–147PubMed
42.
Zurück zum Zitat Salaverria I, Royo C, Carvajal-Cuenca A et al (2013) CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 121(8):1394–1402PubMedPubMedCentral Salaverria I, Royo C, Carvajal-Cuenca A et al (2013) CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 121(8):1394–1402PubMedPubMedCentral
43.
Zurück zum Zitat Salaverria I, Martin-Guerrero I, Wagener R et al (2014) A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B‑cell lymphomas resembling Burkitt lymphoma. Blood 123(8):1187–1198PubMedPubMedCentral Salaverria I, Martin-Guerrero I, Wagener R et al (2014) A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B‑cell lymphomas resembling Burkitt lymphoma. Blood 123(8):1187–1198PubMedPubMedCentral
44.
Zurück zum Zitat Sander S, Calado DP, Srinivasan L et al (2012) Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22(2):167–179PubMedPubMedCentral Sander S, Calado DP, Srinivasan L et al (2012) Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22(2):167–179PubMedPubMedCentral
45.
Zurück zum Zitat Schmatz AI, Streubel B, Kretschmer-Chott E et al (2011) Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma. J Clin Oncol 29(11):1445–1451PubMed Schmatz AI, Streubel B, Kretschmer-Chott E et al (2011) Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma. J Clin Oncol 29(11):1445–1451PubMed
46.
Zurück zum Zitat Schmidt J, Salaverria I, Haake A et al (2014) Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma. Leukemia 28(5):1103–1112PubMed Schmidt J, Salaverria I, Haake A et al (2014) Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma. Leukemia 28(5):1103–1112PubMed
47.
Zurück zum Zitat Schmidt J, Gong S, Marafioti T et al (2016) Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood 128(8):1101–1111PubMedPubMedCentral Schmidt J, Gong S, Marafioti T et al (2016) Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood 128(8):1101–1111PubMedPubMedCentral
49.
Zurück zum Zitat Schmitz R, Young RM, Ceribelli M et al (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490(7418):116–120PubMedPubMedCentral Schmitz R, Young RM, Ceribelli M et al (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490(7418):116–120PubMedPubMedCentral
50.
Zurück zum Zitat Scott DW, Wright GW, Williams PM et al (2014) Determining cell-of-origin subtypes of diffuse large B‑cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123(8):1214–1217PubMedPubMedCentral Scott DW, Wright GW, Williams PM et al (2014) Determining cell-of-origin subtypes of diffuse large B‑cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123(8):1214–1217PubMedPubMedCentral
51.
Zurück zum Zitat Staiger AM, Ziepert M, Horn H et al (2017) Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B‑cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin’s Lymphoma Study Group. J Clin Oncol 35(22):2515. https://doi.org/10.1200/JCO.2016.70.3660 PubMed Staiger AM, Ziepert M, Horn H et al (2017) Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B‑cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin’s Lymphoma Study Group. J Clin Oncol 35(22):2515. https://​doi.​org/​10.​1200/​JCO.​2016.​70.​3660 PubMed
52.
Zurück zum Zitat Swerdlow SH, Campo E, Jaffe ES et al (Hrsg) (2008) WHO classification of tumours of haematopoetic and lymphoid tissues. IARC Press, Lyon Swerdlow SH, Campo E, Jaffe ES et al (Hrsg) (2008) WHO classification of tumours of haematopoetic and lymphoid tissues. IARC Press, Lyon
53.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL et al (Hrsg) (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, 4. Aufl. International Agency for Research on Cancer, Lyon Swerdlow SH, Campo E, Harris NL et al (Hrsg) (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, 4. Aufl. International Agency for Research on Cancer, Lyon
54.
Zurück zum Zitat Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364(24):2305–2315PubMedPubMedCentral Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364(24):2305–2315PubMedPubMedCentral
55.
Zurück zum Zitat Treon SP, Xu L, Yang G et al (2012) MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 367(9):826–833PubMed Treon SP, Xu L, Yang G et al (2012) MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 367(9):826–833PubMed
56.
Zurück zum Zitat Vardi A, Dagklis A, Scarfò L et al (2013) Immunogenetics shows that not all MBL are equal. Blood 121(22):4521–4528PubMed Vardi A, Dagklis A, Scarfò L et al (2013) Immunogenetics shows that not all MBL are equal. Blood 121(22):4521–4528PubMed
57.
Zurück zum Zitat Wang SA, Wang L, Hochberg EP et al (2005) Low histologic grade follicular lymphoma with high proliferation index. Am J Surg Pathol 29(11):1490–1496PubMed Wang SA, Wang L, Hochberg EP et al (2005) Low histologic grade follicular lymphoma with high proliferation index. Am J Surg Pathol 29(11):1490–1496PubMed
58.
Zurück zum Zitat Wang T, Feldman AL, Wada DA et al (2014) GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 123(19):3007–3015PubMedPubMedCentral Wang T, Feldman AL, Wada DA et al (2014) GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 123(19):3007–3015PubMedPubMedCentral
59.
Zurück zum Zitat Xerri L, Dirnhofer S, Quintanilla-Martinez L et al (2016) The heterogeneity of follicular lymphomas. Virchows Arch 468(2):127–139PubMed Xerri L, Dirnhofer S, Quintanilla-Martinez L et al (2016) The heterogeneity of follicular lymphomas. Virchows Arch 468(2):127–139PubMed
60.
Zurück zum Zitat Xochelli A, Kalpadakis C, Gardiner A et al (2014) Clonal B‑cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin. Blood 123(8):1199–1206PubMed Xochelli A, Kalpadakis C, Gardiner A et al (2014) Clonal B‑cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin. Blood 123(8):1199–1206PubMed
Metadaten
Titel
Revidierte Fassung der 4. Ausgabe der WHO-Klassifikation maligner Lymphome
Was ist neu?
verfasst von
Prof. Dr. G. Ott
W. Klapper
A. C. Feller
M. L. Hansmann
P. Möller
H. Stein
A. Rosenwald
F. Fend
Publikationsdatum
17.07.2018
Verlag
Springer Medizin
Erschienen in
Die Pathologie / Ausgabe 2/2019
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-018-0456-4

Weitere Artikel der Ausgabe 2/2019

Die Pathologie 2/2019 Zur Ausgabe

Mitteilungen der Deutschen Gesellschaft für Pathologie

Mitteilungen der Deutschen Gesellschaft für Pathologie

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.